Corticosteroid Dependent Adult Chronic Immune Thrombocytopenia
Conditions
Interventions
Eltrombopag 12.5mg to 50mg
Sponsors
Hematology/ Oncology, Iwate Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult (over than 20 years old) chronic ITP patients (<10x104/&#181;l) under the treatment of corticosteroid 2. One of the followings A. Corticosteroid dependent (refractory) B. Strong request of patient for discontinuation of corticosteroid treatment C. Any medical reason for difficulty of continuation of corticosteroid treatment 3. Negative anti-phospholipid antibody 4. Obtainable written informed consent
Exclusion criteria
Exclusion criteria: 1. Any history of thrombo-embolic events. 2. Any hereditary disorder that may cause thrombo- embolic events such as ATIII deficiency or Protein C/S deficiency. 3. Any history of allergy/ intolerance to the study drug. 4. Pregnant, possibly pregnant and lactating women as well as women who intend to become pregnant within the proposed study period. 5. Any concomitant drugs or therapy that may influence the result of the study. 6. Renal or hepatic dysfunction/insufficiency. 7. HIV infection, HBV infection 7. Subjects judged as unsuitable for participation in the study for any reason by the physicians in charge of the study. 8. Unable to participate all sessions of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients who can replace prednisolone with eltrombopag | — |
Countries
Japan
Outcome results
None listed